The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro
Authors:
- Diede W. M. BroekaartDBDiede W. M. Broekaart
- Till S. ZimmerTZTill S. Zimmer
- Sophie T. CohenSCSophie T. Cohen
- Rianne TessersRTRianne Tessers
- Jasper J. AninkJAJasper J. Anink
- Helga E. de VriesHVHelga E. de Vries
- Jan A. GorterJGJan A. Gorter
- Roger PradesRPRoger Prades
- Eleonora AronicaEAEleonora Aronica
- Erwin A. van VlietEVErwin A. van Vliet
Open Access
- 29 August 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2117
Abstract
Matrix metalloproteinases (MMPs) are endopeptidases responsible for the cleavage of intra- and extracellular proteins. Several brain MMPs have been implicated in neurological disorders including epilepsy. We recently showed that the novel gelatinase inhibitor ACT-03 has disease-modifying effects in models of epilepsy. Here, we studied its effects on neuroinflammation and blood–brain barrier (BBB) integrity. Using the rapid kindling rat model of epilepsy, we examined whether ACT-03 affected astro- and microgliosis in the brain using immunohistochemistry. Cellular and molecular alterations were further studied in vitro using human fetal astrocyte and brain endothelial cell (hCMEC/D3) cultures, with a focus on neuroinflammatory markers as well as on barrier permeability using an endothelial and astrocyte co-culture model. We observed less astro- and microgliosis in the brains of kindled animals treated with ACT-03 compared to control vehicle-treated animals. In vitro, ACT-03 treatment attenuated stimulation-induced mRNA expression of several pro-inflammatory factors in human fetal astrocytes and brain endothelial cells, as well as a loss of barrier integrity in endothelial and astrocyte co-cultures. Since ACT-03 has disease-modifying effects in epilepsy models, possibly via limiting gliosis, inflammation, and barrier integrity loss, it is of interest to further evaluate its effects in a clinical trial.Keywords
Funding Information
- European Union’s Seventh Framework Programme (602102, 16-05, 20-11, 952455)
- EpilepsieNL (602102, 16-05, 20-11, 952455)
- European Union Horizon 2020 WIDESPREAD-05-2020-Twinning (602102, 16-05, 20-11, 952455)
This publication has 128 references indexed in Scilit:
- The hCMEC/D3 cell line as a model of the human blood brain barrierFluids and Barriers of the CNS, 2013
- Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic StrokeFrontiers in Neurology, 2013
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse modelNeurobiology of Aging, 2012
- Increased coupling and altered glutamate transport currents in astrocytes following kainic-acid-induced status epilepticusNeurobiology of Disease, 2010
- Role of Matrix Metalloproteinase-9 Dimers in Cell MigrationJournal of Biological Chemistry, 2010
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- Brain Extracellular Matrix in NeurodegenerationBrain Pathology, 2009
- Transforming growth factor‐beta 1 (TGF‐β1) induces angiogenesis through vascular endothelial growth factor (VEGF)‐mediated apoptosisJournal of Cellular Physiology, 2009
- Interleukin-1 and neuronal injuryNature Reviews Immunology, 2005